Research programme: CNS and neurological disorder therapeutics - ACADIA

Drug Profile

Research programme: CNS and neurological disorder therapeutics - ACADIA

Alternative Names: AC-131; AC-186; ERβ programme - ACADIA; Estrogen receptor beta agonists - ACADIA; Nurr1 programme - ACADIA; Nurr1-retinoid X receptor agonists - ACADIA; Nurr1-RXR agonists - ACADIA

Latest Information Update: 24 Dec 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Dopamine modulators; Estrogen receptor beta agonists; Nuclear receptor subfamily 4 group A member 2 agonists; Retinoid X receptor agonists; Selective estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Multiple sclerosis; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 21 Dec 2012 Preclinical trials in Multiple sclerosis in USA (unspecified route)
  • 20 Dec 2012 ACADIA Pharmaceuticals to receive grant from Fast Forward and EMD Serono for preclinical development in Multiple sclerosis
  • 30 Mar 2012 Preclinical development in Parkinson's disease is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top